Semaglutide tablets are the first and currently the only oral glucagon-like peptide 1 (GLP-1) receptor agonist. The approval is based on the efficacy and safety of oral semaglutide in 10 PIONEER clinical trials involving a total of 9543 adults with type 2 diabetes
Glucagon-Like Peptide 1 receptor agonists (GLP-1Ras) has been evaluated for its several positive eff...
Early and effective glycemic control can prevent or delay the complications associated with type 2 d...
Summary: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are used for the treatment of type 2 di...
Glucagon-like peptide 1 receptor agonists (GLP1-RA) are prominent agents in the therapeutics of type...
The gastrointestinal tract secretes gut hormones in response to food consumption, and some of these ...
GLP-1 receptor agonists (GLP-1RAs) are recommended for patients with type 2 diabetes (T2D), particul...
Type 2 diabetes (T2DM) is a chronic medical condition affecting millions of individuals worldwide. T...
Fernando Gomez-Peralta, Cristina Abreu Endocrinology and Nutrition Unit, Hospital General de Segovi...
Glucagon-like peptide-1 (GLP-1)–based therapy improves glycaemic control through multiple mechanisms...
The glucagon-like peptide-1 receptor agonists (GLP-1RAs) have important beneficial effects on glycem...
Today, glucagon-like peptide-1 (GLP-1) receptor agonists are established glucose-lowering drugs used...
Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data ar...
Since the approval of subcutaneous glucagon-like peptide-1 receptor agonists, this therapeutic class...
The glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of injected drugs for the trea...
Introduction: Glucagon-like peptide-1 (GLP-1) is produced by the gut, and in a glucose-dependent man...
Glucagon-Like Peptide 1 receptor agonists (GLP-1Ras) has been evaluated for its several positive eff...
Early and effective glycemic control can prevent or delay the complications associated with type 2 d...
Summary: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are used for the treatment of type 2 di...
Glucagon-like peptide 1 receptor agonists (GLP1-RA) are prominent agents in the therapeutics of type...
The gastrointestinal tract secretes gut hormones in response to food consumption, and some of these ...
GLP-1 receptor agonists (GLP-1RAs) are recommended for patients with type 2 diabetes (T2D), particul...
Type 2 diabetes (T2DM) is a chronic medical condition affecting millions of individuals worldwide. T...
Fernando Gomez-Peralta, Cristina Abreu Endocrinology and Nutrition Unit, Hospital General de Segovi...
Glucagon-like peptide-1 (GLP-1)–based therapy improves glycaemic control through multiple mechanisms...
The glucagon-like peptide-1 receptor agonists (GLP-1RAs) have important beneficial effects on glycem...
Today, glucagon-like peptide-1 (GLP-1) receptor agonists are established glucose-lowering drugs used...
Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data ar...
Since the approval of subcutaneous glucagon-like peptide-1 receptor agonists, this therapeutic class...
The glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of injected drugs for the trea...
Introduction: Glucagon-like peptide-1 (GLP-1) is produced by the gut, and in a glucose-dependent man...
Glucagon-Like Peptide 1 receptor agonists (GLP-1Ras) has been evaluated for its several positive eff...
Early and effective glycemic control can prevent or delay the complications associated with type 2 d...
Summary: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are used for the treatment of type 2 di...
DOI
Add to ORKG